ArticleCancer discovery2024
The Hallmarks of Precancer.
Abstract read
In one paragraph
Article in Cancer discovery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Spatial Integration of Protein and Chromosomal States Reveals Early Copy-Number Changes and Genotype-Associated Immune Neighborhoods in Serous Ovarian Cancer Evolution.Cancer discovery · 2026Article
- Biological aging and generational shifts in early-onset cancer risk.Nature medicine · 2026Article
- Molecular pathology of intraductal papillary mucinous neoplasms of the pancreas: current understanding and perspectives on malignant progression.Journal of gastroenterology · 2026Review
- Integrated epidemiological and molecular data inform the relationship between precancer and cancer states of esophageal adenocarcinoma.Nature medicine · 2026Article
- NADPH-producing enzymes restrict the formation of pancreatic precancerous lesions.Nature metabolism · 2026Article
- Single-cell spatial atlas of the aging human breast.Nature aging · 2026Article
- Rethinking the microenvironment's role in chemical-induced malignancy.Toxicological sciences : an official journal of the Society of Toxicology · 2026Review
- Precancerous microenvironment: A signalling perspective.Current opinion in cell biology · 2026Review
- Cellular senescence in precancer lesions and early-stage cancers.Cancer cell · 2026Review
- Signaling pathways and targeted interventions for precancers.Signal transduction and targeted therapy · 2026Review
- Cell state dynamics during early stages of serous endometrial carcinoma.The Journal of pathology · 2025Article
- Precision Prevention Studies: A Targeted Approach to Cancer Prevention.Cancer prevention research (Philadelphia, Pa.) · 2025Review
- Spatial Analysis of Hereditary Diffuse Gastric Cancer Reveals Indolent Phenotype of Signet Ring Cell Precursors.Molecular cancer research : MCR · 2025Article
- Deciphering cholangiocarcinoma heterogeneity and specific progenitor cell niche of extrahepatic cholangiocarcinoma at single-cell resolution.Journal of hematology & oncology · 2025Article
- Multimodal Spatial Profiling Reveals Immune Suppression and Microenvironment Remodeling in Fallopian Tube Precursors to High-Grade Serous Ovarian Carcinoma.Cancer discovery · 2025Article
- FOLR2Cell communication and signaling : CCS · 2025Review
- Cerumenogram as an assay for the metabolic diagnosis of precancer, cancer, and cancer remission.Scientific reports · 2025Article
- Advances and global trends of precancerous lesions of gastric cancer: A bibliometric analysis.World journal of gastrointestinal oncology · 2025Article
- Enhancing disease risk gene discovery by integrating transcription factor-linked trans-variants into transcriptome-wide association analyses.Nucleic acids research · 2025Article
- Potential signaling pathways, biomarkers, natural drugs, and chronic myeloid leukemia therapeutics.Frontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Mary M Stangis *McArdle Laboratory for Cancer Research, Department of Oncology, University of Wisconsin-Madison, Madison, Wisconsin.ORCID 0000-0003-4139-0861
Zhengyi Chen *Chemical and Physical Biology Program, Vanderbilt University School of Medicine, Nashville, Tennessee.ORCID 0000-0003-4774-945X
Jimin Min *Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-2309-7875
Sarah E Glass *Epithelial Biology Center, Vanderbilt University Medical Center, Nashville, Tennessee.ORCID 0000-0002-0642-2656
Jordan O Jackson *Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington.ORCID 0000-0002-1225-912X
Megan D Radyk *Department of Molecular & Integrative Physiology, University of Michigan Medical School, Ann Arbor, Michigan.ORCID 0000-0002-3660-2906
Xen Ping HoiDepartment of Urology, Houston Methodist Research Institute, Houston, Texas.ORCID 0000-0001-7610-7291
W Nathaniel BrennenGenitourinary Cancer Disease Division, Department of Oncology, Johns Hopkins Medicine, Baltimore, Maryland.ORCID 0000-0001-9807-7433
Ming YuTranslational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington.ORCID 0000-0001-8692-6135
Huy Q DinhMcArdle Laboratory for Cancer Research, Department of Oncology, University of Wisconsin-Madison, Madison, Wisconsin.ORCID 0000-0002-3307-1126
Robert J CoffeyEpithelial Biology Center, Vanderbilt University Medical Center, Nashville, Tennessee.ORCID 0000-0002-2180-3844
Martha J ShrubsoleVanderbilt-Ingram Cancer Center, Nashville, Tennessee.ORCID 0000-0002-5591-7575
Keith S ChanDepartment of Urology, Houston Methodist Research Institute, Houston, Texas.ORCID 0000-0003-1670-8508
William M GradyTranslational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington.ORCID 0000-0002-0129-7809
Srinivasan YegnasubramanianGenitourinary Cancer Disease Division, Department of Oncology, Johns Hopkins Medicine, Baltimore, Maryland.ORCID 0000-0003-0744-6606
Costas A LyssiotisDepartment of Molecular & Integrative Physiology, University of Michigan Medical School, Ann Arbor, Michigan.ORCID 0000-0001-9309-6141
Anirban MaitraDepartment of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-7923-9978
Richard B HalbergMcArdle Laboratory for Cancer Research, Department of Oncology, University of Wisconsin-Madison, Madison, Wisconsin.ORCID 0000-0001-6886-1534
Neelendu DeyTranslational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington.ORCID 0000-0001-8825-5689
Ken S LauChemical and Physical Biology Program, Vanderbilt University School of Medicine, Nashville, Tennessee.ORCID 0000-0001-8438-0319
Funding
Vanderbilt-Ingram Cancer Center SPORE in Gastrointestinal CancerP50CA236733 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI STEPHEN W. FESIK · 2019 to 2026
$19.6MProject 3: Inhibiting Oxidative Phosphorylation in Pancreatic CancerP50CA221707 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KOPETZ, SCOTT, MAITRA, ANIRBAN · 2019 to 2023
$11.0MUnderstanding adenoma progression: Interplay among tissue microenvironment, clonal architecture, and gut microbiomeU54CA274374 · NCI · FRED HUTCHINSON CANCER CENTER · PI Neelendu Dey · 2022 to 2026
$10.7MTraining in Cancer Biology Training GrantT32CA009135 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI SUGDEN, WILLIAM M. · 1985 to 2024
$10.4MThe stromal microenvironment as a co-organizer of bladder carcinogenesis and progressionU54CA274375 · NCI · METHODIST HOSPITAL RESEARCH INSTITUTE · PI Keith Syson Chan, Dan Theodorescu · 2022 to 2026
$10.2MShaping the Microenvironment by DPEP1 Facilitates Adenoma ProgressionU54CA274367 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Bhuminder Singh · 2022 to 2026
$9.7MTumor Microenvironment Crosstalk Drives Early Lesions in Pancreatic CancerU54CA274371 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI ANIRBAN MAITRA, Marina Pasca Di Magliano · 2022 to 2026
$9.5MTranslational imaging biomarkers of the tumor microenvironment in early prostate cancerU54CA274370 · NCI · JOHNS HOPKINS UNIVERSITY · PI Srinivasan Yegnasubramanian · 2022 to 2026
$9.1MTuft cell heterogeneity in function, lineage, and structure in ileal inflammatory diseaseR01DK103831 · NIDDK · VANDERBILT UNIVERSITY · PI LAU, KEN S · 2016 to 2024
$4.4MThe role of the senescent microenvironment on cancer initiating cells in the colon.U01AG077920 · NIA · FRED HUTCHINSON CANCER RESEARCH CENTER · PI GRADY, WILLIAM MALLORY · 2021 to 2025
$2.6MTranslational Science of Gastrointestinal Cancer Initiation and ProgressionR50CA233042 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Ming Yu · 2018 to 2026
$2.4MNCI NIH HHS P50 CA221707NCI NIH HHS P50 CA236733NCI NIH HHS R50 CA233042NCI NIH HHS T32 CA009135NCI NIH HHS U54 CA274367NCI NIH HHS U54 CA274370NCI NIH HHS U54 CA274371NCI NIH HHS U54 CA274374NCI NIH HHS U54 CA274375NIA NIH HHS U01 AG077920NIDDK NIH HHS R01 DK103831
Abstract
Research on precancers, as defined as at-risk tissues and early lesions, is of high significance given the effectiveness of early intervention. We discuss the need for risk stratification to prevent overtreatment, an emphasis on the role of genetic and epigenetic aging when considering risk, and the importance of integrating macroenvironmental risk factors with molecules and cells in lesions and at-risk normal tissues for developing effective intervention and health policy strategies.
Indexed as
Precancerous ConditionsHumansRisk Factors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.